Published in Health Business Week, November 18th, 2005
The share issue, which is secured to 100% by commitments from existing shareholders and new investors, will raise about SEK 160 million before issue expenses.
The main purpose of the offering is to finance the further development of the company's candidate drugs. The capital raised makes it possible to take several product candidates to the clinical phase.
In a short period the company has taken four product candidates from the preclinical research phase to the regulated development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.